Raltegravir Intensification in Antiretroviral-treated Patients Exhibiting a Suboptimal CD4+ T Cell Response

NCT00631449 Phase 4 COMPLETED Results posted

The purpose of this study is to determine whether treatment with Raltegravir further decreases HIV viral replication in HAART-suppressed, HIV-infected patients, potentially improving immune response to antiretroviral therapy.

Details

Lead sponsor	University of California, San Francisco
Phase	Phase 4
Status	COMPLETED
Enrolment	30
Start date	2008-02
Completion	2010-03

Conditions

• HIV Infections

Interventions

• Raltegravir
• Placebo

Primary outcomes

• Number of Participants in Each Group (Study Drug vs. Placebo) With Undetectable Plasma HIV-1 RNA, as Measured by an Ultra-sensitive Assay With a Limit of Detection of 1 Copy/mL at Week 12. — Week 12

Countries

United States